These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 5421032)

  • 1. Electrophoresis of guinea-pig complement components (C3, C5, C6, C7, C8 and C9) on polyacrylamide gel.
    Okada H; Mayumi M; Mukojima T; Sekine T; Torisu M
    Immunology; 1970 Apr; 18(4):493-500. PubMed ID: 5421032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of immune haemolysis by a serum factor found in C3-deficient subjects.
    Kitamura H; Tsuboi M
    Immunology; 1989 Feb; 66(2):264-9. PubMed ID: 2925225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lytic activity of C5-9 complexes for erythrocytes from the species other than sheep: C9 rather than C8-dependent variation in lytic activity.
    Yamamoto KI
    J Immunol; 1977 Oct; 119(4):1482-5. PubMed ID: 894048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trypsin-activated complex of human factor B with cobra venom factor (CVF), cleaving C3 and C5 and generating a lytic factor for unsensitized guinea pig erythrocytes. I. Generation of the activated complex.
    Miyama A; Kato T; Horai S; Yokoo J; Kashiba S
    Biken J; 1975 Dec; 18(4):193-204. PubMed ID: 1218074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of the fifth and sixth component of the complement system: similarities between C5b6 and C(56)a with respect to lytic enhancement by cell-bound C3b or A2C, and species preferences of target cell.
    Hänsch GM; Hammer CH; Mayer MM; Shin ML
    J Immunol; 1981 Sep; 127(3):999-1002. PubMed ID: 6911149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The activation of C5 in the fluid phase and in the absence of C3 through the classical pathway of the complement system.
    Kitamura H; Tsuboi M; Nagaki K
    Immunology; 1986 Jul; 58(3):459-65. PubMed ID: 3733147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The attack phase of human complement: differentiation between membrane binding and complex formation by the detection of neoantigen expression in situ. A morphometric immunoferritin study.
    Balkarowa-Ständer J; Rother U; Rauterberg EW
    J Immunol; 1981 Sep; 127(3):1089-93. PubMed ID: 7264298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complement lysis of human erythrocytes. III. Differing effectiveness of human and guinea pig C9 on normal and paroxysmal nocturnal hemoglobinuria cells.
    Rosenfeld SI; Packman CH; Jenkins DE; Countryman JK; Leddy JP
    J Immunol; 1980 Nov; 125(5):2063-8. PubMed ID: 6776186
    [No Abstract]   [Full Text] [Related]  

  • 9. C56 formation in the reaction mixture of isolated complement components through the classical complement pathway.
    Kitamura H; Tsuboi M; Nagaki K
    Int Arch Allergy Appl Immunol; 1985; 78(1):101-7. PubMed ID: 4030125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of the fifth and sixth components of the human complement system: C6-dependent cleavage of C5 in acid and the formation of a bimolecular lytic complex, C5b,6a.
    Hammer CH; Hänsch G; Gresham HD; Shin ML
    J Immunol; 1983 Aug; 131(2):892-8. PubMed ID: 6863934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complement lysis of human erythrocytes. II. A unique interaction of human C8 and C9 with paroxysmal nocturnal hemoglobinuria erythrocytes.
    Packman CH; Rosenfeld SI; Jenkins DE; Leddy JP
    J Immunol; 1980 Jun; 124(6):2818-23. PubMed ID: 7189536
    [No Abstract]   [Full Text] [Related]  

  • 12. Physicochemical characterization of the fifth (C5), sixth (C6), seventh (C7), eighth (C8) and ninth (C9) component of guinea pig complement.
    König W; Bitter-Suermann D; Dierich M; Hadding U
    Eur J Immunol; 1971 Nov; 1(5):372-6. PubMed ID: 5157761
    [No Abstract]   [Full Text] [Related]  

  • 13. Studies on the mechanism of bacterial resistance to complement-mediated killing. VI. IgG increases the bactericidal efficiency of C5b-9 for E. coli 0111B4 by acting at a step before C5 cleavage.
    Joiner KA; Goldman RC; Hammer CH; Leive L; Frank MM
    J Immunol; 1983 Nov; 131(5):2570-5. PubMed ID: 6355297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Independent and consecutive action of the complement components C5, C6 and C7 in immune hemolysis. I. Preparation of EAC1-5 with purified guinea pig C3 and C5.
    Bitter-Suermann D; Hadding U; Melchert F; Wellensiek HJ
    Immunochemistry; 1970 Dec; 7(12):955-65. PubMed ID: 5503627
    [No Abstract]   [Full Text] [Related]  

  • 15. A study of complement components C3, C5, C6, C7, C8 and C9 in chronic membranoproliferative glomerulonephritis, systemic lupus erythematosus, poststreptococcal nephritis, idiopathic nephrotic syndrome and anaphylactoid purpura.
    Geiger H; Good RA; Day NK
    Z Kinderheilkd; 1975; 119(4):269-78. PubMed ID: 49134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of terminal complement components by human keratinocytes.
    Timár KK; Dallos A; Kiss M; Husz S; Bos JD; Asghar SS
    Mol Immunol; 2007 Apr; 44(10):2578-86. PubMed ID: 17267037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The hemolytic equivalence of human, guinea pig and canine complement proteins.
    Sargent AU; Johnson SB
    Immunol Commun; 1980; 9(5):453-63. PubMed ID: 6903556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A specific method for purification of the second component of guinea pig complement and a chemical evaluation of the one-hit theory.
    Mayer MM; Miller JA; Shin HS
    J Immunol; 1970 Aug; 105(2):327-41. PubMed ID: 5433696
    [No Abstract]   [Full Text] [Related]  

  • 19. Two anticomplementary factors in cobra venom: hemolysis of guinea pig erythrocytes by one of them.
    Ballow M; Cochrane CG
    J Immunol; 1969 Nov; 103(5):944-52. PubMed ID: 4981797
    [No Abstract]   [Full Text] [Related]  

  • 20. Species-restricted target cell lysis by human complement: complement-lysed erythrocytes from heterologous and homologous species differ in their ratio of bound to inserted C9.
    Hu VW; Shin ML
    J Immunol; 1984 Oct; 133(4):2133-7. PubMed ID: 6470486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.